Literature DB >> 12517648

A randomized trial of oral and vaginal misoprostol to manage delivery in cases of fetal death.

Apichart Chittacharoen1, Yongyoth Herabutya, Piyaporn Punyavachira.   

Abstract

OBJECTIVE: To compare the effectiveness and side effects of oral and vaginal misoprostol for the termination of second and third trimester pregnancy with intrauterine fetal death.
METHODS: Eighty pregnant women at 16-41 weeks' gestation with intrauterine fetal death were randomized in two groups to receive either 400 micro g of misoprostol orally every 4 hours (n = 40) or 200 micro g of misoprostol vaginally every 12 hours (n = 40) until the termination of pregnancy was completed. The adverse effects, progress, and outcomes of delivery were assessed.
RESULTS: The groups were similar in age, weight, height, gestational age, parity, and modified Bishop scores before intervention. The mean induction-to-delivery time in the oral group (13.95 [standard deviation (SD) = 5.63] hours) was significantly shorter than the time in the vaginal group (18.87 [SD = 10.38] hours, P =.001). The number of deliveries within 24 hours after the initial drug administration in the oral group (92.5%) was significantly higher than the number in the vaginal group (67.5%, P <.001), and all delivered within 48 hours after the initial drug administration. However, the gastrointestinal side effects in the oral group was significantly higher than in the vaginal group (P =.005).
CONCLUSION: Misoprostol (400 micro g given orally every 4 hours) was more effective than misoprostol (200 micro g given vaginally every 12 hours) for the termination of second and third trimester pregnancy with intrauterine fetal death, but with more gastrointestinal side effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517648     DOI: 10.1016/s0029-7844(02)02506-1

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Route of Delivery in Women With Stillbirth: Results From the Stillbirth Collaborative Research Network.

Authors:  Annelee Boyle; Jessica P Preslar; Carol J R Hogue; Robert M Silver; Uma M Reddy; Robert L Goldenberg; Barbara J Stoll; Michael W Varner; Deborah L Conway; George R Saade; Radek Bukowski; Donald J Dudley
Journal:  Obstet Gynecol       Date:  2017-04       Impact factor: 7.661

Review 2.  Medical treatments for incomplete miscarriage (less than 24 weeks).

Authors:  James P Neilson; Gillian Ml Gyte; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 3.  Medical treatments for incomplete miscarriage.

Authors:  Caron Kim; Sharmani Barnard; James P Neilson; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

Review 4.  Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death.

Authors:  Jodie M Dodd; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

5.  Medical treatment for early fetal death (less than 24 weeks).

Authors:  Marike Lemmers; Marianne Ac Verschoor; Bobae Veronica Kim; Martha Hickey; Juan C Vazquez; Ben Willem J Mol; James P Neilson
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

6.  Methods for managing miscarriage: a network meta-analysis.

Authors:  Jay Ghosh; Argyro Papadopoulou; Adam J Devall; Hannah C Jeffery; Leanne E Beeson; Vivian Do; Malcolm J Price; Aurelio Tobias; Özge Tunçalp; Antonella Lavelanet; Ahmet Metin Gülmezoglu; Arri Coomarasamy; Ioannis D Gallos
Journal:  Cochrane Database Syst Rev       Date:  2021-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.